Approval · Notice of Compliance 21316 · 2018
FETZIMA: Notice of Compliance 21316
Issued September 14, 2018
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 21316
- Date
- September 14, 2018
- Company
- Allergan IncMarkham, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Labelling Only
- Reason
- Change in manufacturer name from "Allergan Pharma Co." to "Allergan Inc."
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| FETZIMA | Not yet assigned | — |
Medicinal ingredients
- LEVOMILNACIPRAN 20 MG per CAP
- LEVOMILNACIPRAN 40 MG per CAP
- LEVOMILNACIPRAN 80 MG per CAP
- LEVOMILNACIPRAN 120 MG per CAP